8.4.3 Auditable

outcome Proportion of patients with a CD4 count <500 cells/μL commencing ART 8.5 Choice of ART 8.5.1 Recommendations  78. We suggest that if abacavir is to be used with ribavirin, the ribavirin should be weight-based dose-adjusted (2C).  79. We recommend when DAAs are to be used there is careful consideration of possible DDIs (1C) and current or archived HIV resistance. All drug interactions should be checked with an expert source (e.g., www.hiv-druginteractions.org).  80. We recommend if boceprevir is to be used, raltegravir (RAL) with tenofovir (TDF) plus emtricitabine (FTC) should be the treatment of choice for those with wild-type HIV (1C): pharmacokinetic data would support etravirine, rilpivirine and maraviroc as alternatives. MAPK Inhibitor Library concentration  81. We recommend if telaprevir is to be used either RAL or standard-dose ritonavir-boosted atazanavir should be used (1C): pharmacokinetic data would support etravirine, rilpivirine and maraviroc as alternatives. Efavirenz may be used but the telaprevir dose needs to be increased to 1125 mg tds.  82. We recommend Cabozantinib price that didanosine (ddI), stavudine (d4T) and zidovudine (ZDV) are avoided (1B). 8.5.2 Good practice point  83. We recommend if patients are commencing ART and DAAs are not being considered, standard first-line ART should be commenced (see BHIVA adult treatment recommendations [54]). 8.5.3 Auditable outcomes Among patients receiving DAAs for HCV

genotype 1 with ART for wild type HIV, the percentage on a recommended regimen, i.e.: raltegravir (RAL) with tenofovir (TDF) plus emtricitabine (FTC) with boceprevir; or RAL or boosted atazanavir with standard dose telaprevir; or efavirenz with increased dose 1125 mg tds telaprevir Proportion of patients on anti-HCV and ART medication with a medication history at each clinic visit documented in the case notes Proportion of patients on DAAs with a record in the notes of a discussion of the

potential for pharmacokinetic interactions with antiretroviral medication and other medication 8.6 Assessment and investigation 8.6.1 Good practice points  84. We recommend all patients have a baseline fibrosis stage assessment.  85. We recommend all patients should be managed by a clinician GPX6 experienced in the management of both HIV and hepatitis C or should be jointly managed by clinicians from HIV and hepatitis backgrounds.  86. We recommend all patients with HCV/HIV infection should be assessed for suitability for treatment of hepatitis C.  87. We recommend consideration for referral to liaison psychiatry services for patients with pre-existing mental health problems prior to initiation of therapy and for patients with treatment-emergent psychiatric problems.  88. We recommend individuals with dependency on alcohol and/or injection drug use are referred to the respective community services before initiation of therapy to minimise non-adherence with treatment.  89.